New Insight into the Role of Adenosine in Demyelination, Stroke and Neuropathic Pain

Elisabetta Coppi*, Ilaria Dettori, Federica Cherchi, Irene Bulli, Martina Venturini, Felicita Pedata and Anna Maria Pugliese

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, Florence, Italy

Keywords: cerebral ischemia, oxygen-glucose deprivation, adenosine receptors, oligodendrocyte differentiation, neuropathic pain, dorsal root ganglion neurons, neuroinflammation

INTRODUCTION

Our group of research has a long-time experience in studying the role/s of adenosine P1 receptors in health and disease conditions of the central nervous system (CNS). The effects of adenosine were investigated in our laboratory by the use of *in vitro* or *in vivo* models. In most recent years, main topics of our research concerned the study of adenosine and its receptors in the physiological processes of myelination and in pathological conditions of ischemia. Most recently, the group addressed the study of adenosine-mediated mechanisms in pain control. Here, we are going to summarize our recent findings.

AREAS OF INTEREST

Role of A2ARs and A2BRs in Oligodendrogliogenesis

Oligodendrocytes (OLs) are the only myelinating cells in the CNS and differentiate throughout adult life from their progenitors, the oligodendrocyte progenitor cells (OPCs), to produce myelin sheets around neuronal axons. Growing evidence indicates that failure of myelin formation in demyelinating diseases, i.e., multiple sclerosis (MS), arises from the disruption of OPC differentiation process (Levine et al., 2001). Hence, therapeutic strategies aimed at fostering this process are largely attractive.

Our attention was devoted to study the role of the different subtypes of adenosine P1 receptors, the adenosine A2A Rs and A2B Rs, in this process. Our group of research significantly contributed to gain insight into the field by demonstrating that selective adenosine A2AR stimulation inhibits OPC maturation by reducing voltage-dependent, sustained, outward K+ currents (IK) sensitive to tetraethylammonium (TEA) (Coppi et al., 2020a). Indeed, adenosine A1R stimulation is also known to promote OPC migration (Othman et al., 2003), another important process aimed to repair brain damage and repopulate the injured site (de Castro and Bribian, 2005).
data are well in keeping with original research from Gallo and coworkers who first demonstrated that TEA, incubated in OPC cultures, reduces the expression of myelin proteins (Gallo et al., 1996).

Successful studies by our laboratory demonstrated that adenosine A2AR agonists, either the prototypical compound BAY60-6583 or the recently synthesized BAY60-6583-analogue P456 (Betti et al., 2018), not only inhibit sustained IK but also transient IK conductances in cultured OPcs (Coppi et al., 2020a). The effect on IK was mimicked and occluded by forskolin, demonstrating its dependency upon intracellular CaMP increase, consistently with Gs-coupling of A2AR and A2BR and with the fact that the Gi-coupled GPR17 (Pugliese et al., 2009b) elicits the opposite effect in OPcs (Coppi et al., 2013b). Importantly, in the same work, we reported that A2BR agonists activate sphingosine-kinase-1 (SphK1), an ubiquitous enzyme responsible for the formation of sphingosine-1-phosphate (SIP). Finally, in vitro silencing of A2BR was sufficient to increase OPC maturation, to inhibit SphK1 expression, and to strikingly raise the levels of SIP lyase, the enzyme devoted to irreversible degradation of SIP. In conclusion, our data demonstrate that A2BR stimulation enhances intracellular SIP levels, whereas A2BR silencing triggers SIP catabolism. Since SIP acts as a mitogen in a variety of cells including OPcs (Jung et al., 2007), we postulate that the antidiagnostic role of A2BR in oligodendrogligenesis is exerted by increasing intracellular SIP levels. These results are particularly attractive since the levels of S1P, an ubiquitous lipid mediator, are directly regulated by the activity of SphK1/SIP pathway (Betti et al., 2018; Pugliese et al., 2009b), opposite effect in OPCs (Coppi et al., 2013b). Importantly, in the same work, we reported that A2BR agonists activate sphingosine-kinase-1 (SphK1), an ubiquitous enzyme responsible for the formation of sphingosine-1-phosphate (SIP). Finally, in vitro silencing of A2BR was sufficient to increase OPC maturation, to inhibit SphK1 expression, and to strikingly raise the levels of SIP lyase, the enzyme devoted to irreversible degradation of SIP. In conclusion, our data demonstrate that A2BR stimulation enhances intracellular SIP levels, whereas A2BR silencing triggers SIP catabolism. Since SIP acts as a mitogen in a variety of cells including OPcs (Jung et al., 2007), we postulate that the antidiagnostic role of A2BR in oligodendrogligenesis is exerted by increasing intracellular SIP levels. These results are particularly attractive since the levels of S1P, an ubiquitous lipid mediator, are directly regulated by the activity of SphK1/SIP pathway (Betti et al., 2018; Pugliese et al., 2009b).

Role of Adenosine A2A Rs and A2BRs in Brain Ischemia

A main topic of our research group concerns the role of different P1 receptor subtypes in modulating the damage inflicted to neurons and glia by ischemia. To this purpose, both the in vitro model of oxygen and glucose deprivation (OGD) in rat hippocampal slices or the in vivo model of ischemia induced by middle cerebral artery occlusion (MCAo) in the rat were used. It is well accepted that adenosine released during brain ischemia exerts a neuroprotective role by A1R-mediated mechanisms (Pedata et al., 2016). However, as A1R-selective agonists became clinically less and less attractive due to important side effects such as bradycardia and sedation (Sollevi, 1986; Vonlubitz et al., 1994), our research focused on A2AR and A2BR subtypes. In the in vitro OGD model in acute rat hippocampal slices, we monitored the excitotoxic damage mediated by excessive glutamate release during a severe OGD insult of 7 or 9 min (Pugliese et al., 2006; Pugliese et al., 2009a; Colotta et al., 2012). Purines are important moderators of neuronal damage during OGD (Coppi et al., 2007a; Maraula et al., 2014). Selective antagonists of adenosine A2ARs, the SCH58261 and SCH442416, protect from the OGD-induced irreversible disappearance of field excitatory post-synaptic potentials (fEPSPs) and from the appearance of anoxic depolarization (AD), an unequivocal sign of neuronal injury. The A2AR antagonists also delay AD onset invariably during a long period, 30 min, OGD in the CA1 region (Pugliese et al., 2009a) or in the dentate gyrus (DG) (Maraula et al., 2013) of the hippocampus. In the DG, A2BR antagonists also restore the number of 5-bromo-2-deoxyuridine-positive (BrdU*) newborn neurons 6 h after the end of the insult (Maraula et al., 2013), limit the extent of CA1 damage to neurons and glia assessed by propidium iodide permeability, and reduce astrocyte activation (Pugliese et al., 2009a).

Similar results were later found with antagonists to the “partner” adenosinergic receptor, i.e., the A2BR subtype. The compounds MRS1754 and PSB603, by blocking the A2BR, protected CA1 hippocampal slices from OGD-induced damage by preventing irreversible synaptic failure and AD appearance induced by OGD and counteracted CA1 neuronal loss, astrocyte activation, and cytochrome C release (Fusco et al., 2018). In line with previous literature (Goncalves et al., 2015), we confirmed that protection by the adenosine A2BR antagonists is attributable to diminished glutamate release since the A2BR agonist BAY60-6583, and its analogue P456, significantly decreased hippocampal paired pulse facilitation (PPF) (Fusco et al., 2019), an electrophysiological paradigm used to detect presynaptic neuromodulation of glutamate release (Regehr, 2012).

Consistent with previous results, we found that the selective A2AR antagonist, SCH58261, acutely (5 min) or subchronically (5 min, 6 h, and 20 h) administered in the in vivo model of permanent MCAo (pMCAo) in the rat, 24 h thereafter, was protective against neurological deficit and brain damage (Melani et al., 2003; Melani et al., 2006; Melani et al., 2009). Such protection can be related to the activation of deleterious pathways of MAPK expressed in microglia, such as p38, or JNK, expressed in mature OLs and in OPcs (Melani et al., 2006), which is considered an inhibitory molecule that can hinder myelin reconstitution and neuron functionality (Melani et al., 2009). Such a protective effect induced by adenosine A2BR antagonism in the first hours after ischemia found a valuable explanation in the ability to control excessive glutamate extracellular concentrations as detected by the technique of cerebral microdialysis (Melani et al., 2003) and the ensuing acute excitotoxicity after ischemia.

In an apparent paradoxical manner, we found that, in the model of transient, 1 h, MCAo (tMCAo), not the antagonist but the agonist at the A2AR, CGS21680, exerted protective effects. However, this observation was made later from ischemia induction, i.e., 7 days after ischemia. Indeed, the chronic administration (twice/day for 7 days) with CGS21680 induced protection from neurological deficit, weight loss, cortical infarct volume, myelin disorganization, and glial activation (Melani et al., 2014). Without excluding that protection by A2AR agonists is attributable to central effects, such as increasing expression and release of neurotrophic factors (Sebastiao and Ribeiro, 2009), data reported by our research group point toward a protective effect due to peripheral A2AR activation. A2ARs are expressed on blood cells where they definitely reduce adhesion cell factor production, platelet aggregation and neutrophil activation, exerting, therefore, an antithrombotic, antioxidant and anti-inflammatory effect. Accordingly, two days after tMCAo, chronic treatment with
CGS21680 reduced the number of infiltrated blood cells in the ischemic areas (Melani et al., 2014).

Most recently, we found similar results by studying the effect of BAY60-6583 (administered twice/day for 7 days in the tMCAo model), a selective agonist of the other A2R subtype, that the A2BR in most cases is coexpressed with A2ARs on hematic cells where it inhibits vascular adhesion (Yang et al., 2006) and migration of inflammatory cells (Wakai et al., 2001; Konrad et al., 2012). Two days after ischemia, the A2BR agonist reduced blood cell infiltration in the ischemic cortex (Dettori et al., 2020). Interestingly, 7 days after ischemia, the A2BR agonist also decreased TNF-α and increased IL-10 levels in the blood (Dettori et al., 2020). Both factors are considered valuable blood markers of the brain damage following an ischemic insult (Jickling and Sharp, 2011). These results stress the key research questions of the predictive value of blood biomarkers in stroke.

By and large, results underlie that, after hypoxia/ischemia, brain injury results from a complex sequence of pathophysiological events that evolve over time: a primary acute mechanism of excitotoxicity and perinfarct depolarizations followed by a secondary brain injury activation triggered by protracted neuroinflammation (Coppi et al., 2019). Information acquired up to now indicate that adenosine A2Rs located on any cell type of the brain and on vascular and blood cells partake in either salvage or demise of the tissue after a stroke. Thus, they all represent important targets for drugs having different therapeutic time-windows after stroke.

**Role of Adenosine A3Rs in Pain Control**

Most recently, our group addressed the study of adenosine-mediated mechanisms of pain control. It is known that agonists at A3R subtype are effective pain suppressors in animal models of chronic constriction injury, chemotherapeutic pain (Janes et al., 2016), and also in colitis-induced visceral hypersensitivity (Lucarini et al., 2020). Their safe pharmacological profile, as shown by clinical trials for other pathologies, i.e., rheumatoid arthritis, psoriasis, and cancer, confirms a realistic translational potential, thus encouraging research studies on the molecular mechanisms underpinning their antinociceptive actions. A number of pathways, involving central or peripheral mechanisms, have been proposed.

Our group recently demonstrated that the prototypical A3R agonist Cl-IB-MECA and the new, highly selective, A3R agonist MRS5980 (Tosh et al., 2014) inhibit the neuronal N-type voltage-dependent Ca\(^{2+}\) current in DRG neurons, a known pain-related current, more efficiently than the A3R agonist CPA (Coppi et al., 2019). Indeed, current-clamp experiments confirmed that Cl-IB-MECA significantly decreased the DRG neuronal firing (Coppi et al., 2019).

Our findings contributed to unveil one of the mechanisms of A3R-based pain control and reinforce the concept of A3R agonists as novel, promising, nonnarcotic agents for chronic pain relief.

**DISCUSSION**

On the whole, our recent findings support the notion of adenosine receptors being involved in a number of central and peripheral nervous system diseases, from stroke and demyelination to neuropathic pain. Beyond the well-known protective effect of A1Rs, whose agonists are unfortunately not devoid of side effects, A1R- and A3R-selective ligands are attractive tools to develop innovative therapeutic strategies. Indeed, A3R antagonists exert significant neuroprotection in the initial (within 24 h) postischemic damage in the brain due to inhibition of glutamate excitotoxicity. Additional neuroprotection by A2AR and/or A2BR antagonists could be due to a promyelinating effect exerted by these compounds by stimulating OPC differentiation. On the other hand, at later phases (i.e., 7 days) after stroke, A3R agonists may attenuate neuroinflammation and immune cell infiltration to reduce brain damage. Finally, recent results emerging from our group revealed one of the mechanisms responsible for A3R-mediated pain control, i.e., inhibition of N-type Ca\(^{2+}\) currents and electrical activity in primary sensory neurons of the DRG, thus supporting these receptors as innovative nonopioid compounds for the treatment of chronic pain.

**AUTHOR CONTRIBUTIONS**

EC, ID, AMP, and FP wrote the paper. FC, EC, ID, MV, and IB performed and analyzed experiments described in the paper. AMP, EC, and FP provided funding. AMP and FP supervised the work.

**FUNDING**

The study was supported by the University of Florence (Fondi Ateneo Ricerca) to AMP, the Ministry of Education, Universities and Research, Italy: MIUR-PRIN 2017CY3J3W_003 to FP, Fondazione Umberto Veronesi to EC (FUV 2020-3299), and Fondazione Italiana Sclerosi Multipla (FISM): 2019/R-Single/036 (AMP) to AMP and EC.

**REFERENCES**

Betti, M., Catarzi, D., Varano, F., Falsini, M., Varani, K., Vincenzi, F., et al. (2018). The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A(2B) receptor. *Eur. J. Med. Chem.* 150, 127–139. doi:10.1016/j.ejmech.2018.02.081

Burnstock, G., and Dale, N. (2015). Purinergic signalling during development and ageing. *Purinergic Sign. 11, 277–305. doi:10.1007/s11302-015-9452-9

Cherchi, F., Fugliese, A. M., and Coppi, E. (2020). Oligodendrocyte precursor cell maturation: role of adenosine receptors. *Neural. Regen. Res. 9, 155. doi:10.3389/ fnccel.2015.00155

Colotta, V., Lenzi, O., Catarzi, D., Varano, F., Squarciapino, L., Costagli, C., et al. (2012). 3-Hydroxy-1H-quinoxaline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies. *Eur. J. Med. Chem.* 54, 470–482. doi:10.1016/j.ejmech.2012.05.036

Coppi, E., Collai, L., Maraula, G., Dettori, I., Melani, A., Pugliese, A. M., et al. (2015). Role of adenosine in oligodendrocyte precursor maturation. *Front. Cell. Neurosci.* 9, 155. doi:10.3389/fncel.2015.00155

Coppi, E., Collai, L., Maraula, G., Pugliese, A. M., and Pedata, F. (2013a). Adenosine A(2A) receptors inhibit delayed rectifier potassium currents and cell differentiation in primary purified oligodendrocyte cultures. *Neuropharmacology.* 73, 301–310. doi:10.1016/j.neuropharm.2013.05.035
Vonlubitz, D., Lin, R. C. S., Melman, N., Ji, X. D., Carter, M. F., and Jacobson, K. A. (1994). Chronic administration of selective adenosine A(1) receptor agonist or antagonist in cerebral-ischemia. *Eur. J. Pharmacol.* 256, 161–167. doi:10.1016/0014-2999(94)90241-0

Wakai, A., Wang, J. H., Winter, D. C., Street, J. T., O’Sullivan, R. G., and Redmond, H. P. (2001). Adenosine inhibits neutrophil vascular endothelial growth factor release and transendothelial migration via A(2B) receptor activation. *Shock.* 15, 297–301. doi:10.1097/00024382-200115040-00008

Yang, D., Zhang, Y., Nguyen, H. G., Koupenova, M., Chauhan, A. K., Makitalo, M., et al. (2006). The A(2B) adenosine receptor protects against inflammation and excessive vascular adhesion. *J. Clin. Invest.* 116, 1913–1923. doi:10.1172/JCI27933

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Coppi, Dettori, Cherchi, Balli, Venturini, Pedata and Pugliese. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.